The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer

Annals of Internal Medicine

Volumn 127, Issue 11, 1997, Pages 973-980

  Sellers, Thomas A ^a   Mink, Pamela J ^a   Cerhan, James R ^b   Zheng, Wei ^a   Anderson, Kristin E ^a   Kushi, Lawrence H ^a   Folsom, Aaron R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0030667719     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-11-199712010-00004     Document Type: Article

References (40)

1. Hoskins KF, Stopler JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995;273:577-85.
2. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992;79:286-94.
3. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-90.
4. Armstrong BK. Oestrogen therapy after the menopause - boon or bane? Med J Aust. 1988;148:213-4.
5. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med. 1991;151:67-72.
6. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-42.
7. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Non-contraceptive hormone use and risk of breast cancer. Cancer Causes Control. 1992;3:475-9.
8. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-93.
9. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst. 1981;67: 815-20.
10. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA. 1987;257:209-15.
11. Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control. 1992;3:433-9.
12. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142:788-95.
13. Mills PK, Beeson WL, Phillips RL, Fraser GE. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer. 1989;64:591-7.
14. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85:1128-32.
15. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-37.
16. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-8.
17. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Jofee M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-75.
18. Blackman JA, Bush TL. Breast cancer and hormone-replacement therapy [Letter]. N Engl J Med. 1995;333:1355-6.
19. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD, et al. Body fat distribution and 5-year risk of death in older women. JAMA. 1993; 269:483-7.
20. Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol. 1990;131:794-803.
21. Bisgard KM, Folsom AR, Hong CP, Sellers TA. Mortality and cancer rates in nonrespondents to a prospective cohort study of older women: 5-year follow-up. Am J Epidemiol. 1994;139:990-1000.
22. Kushi LH, Kaye SA, Folsom AR, Soler JT, Prineas RJ. Accuracy and reliability of self-measurement of body girths. Am J Epidemiol. 1988;128: 740-8.
23. SEER Cancer Statistics Review, 1973-1991: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1994. NIH publication no. 94-2789.
24. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death: Based on the Recommendations of the Ninth Revision Conference, 1975. Geneva: World Health Organization; 1977.
25. Breslow NE, Day NE. Statistical Methods in Cancer Research. Oxford: Oxford Univ Pr; 1987.
26. SAS User's Guide: Statistics. Cary, NC: SAS Institute; 1985.
27. Henderson BE, Pike MC, Bernstein L, Ross, RK. Breast cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. 2d ed. New York: Oxford Univ Pr; 1996:1022-39.
28. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 1993;15:66-79.
29. Nomura AM, Kolonel LN, Hirohata T, Lee J. The association of replacement estrogens with breast cancer. Int J Cancer. 1986;37:49-53.
30. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol. 1991;134:1375-85.
31. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986;54:825-32.
32. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study. Am J Epidemiol. 1991;134:1386-401.
33. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73: 643-51.
34. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. J Natl Cancer Inst. 1996;88:365-71.
35. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk for breast cancer (United States). Cancer Causes Control. 1994;5:491-500.
36. Brinton LA, Hoover RN, Szklo M. Menopausal estrogen use and risk of breast cancer. Cancer. 1981;47:2517-22.
37. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995;6:227-31.
38. Go RC, King MC, Bailey-Wilson J, Elston RC, Lynch HT. Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis. J Natl Cancer Inst. 1983;71:455-61.
39. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of non-contraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health. 1988;78:1479-81.
40. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-61.